Johnson & Johnson Starts 2026 on Firm Footing as Drug Growth Offsets a More Measured MedTech Pace

A raised full-year sales outlook, stronger adjusted earnings and continued momentum in oncology and immunology kept Johnson & Johnson’s growth story intact, even as revenue eased modestly from the prior quarter.

📌 Key Takeaways

Johnson & Johnson opened 2026 with a solid, if not flawless, quarter. First-quarter sales